Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDYMION long-term TAK-935 (OV935) extension study in rare epilepsies
2018-002485-39Phase 2Active
- Sponsor
- Ovid Therapeutics
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of soticlestat in epileptic encephalopathy, sponsored by Ovid Therapeutics. Primary endpoint: Long-term safety and tolerability of TAK-935. Started Apr 2019; status: active.
02
Drugs
soticlestat
03
Conditions
epileptic encephalopathy
Beyond the preview
Go deeper on 2018-002485-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002485-39.